Kidney injuries related to ipilimumab

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

(2011) Katarzyna D. Chmiel et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of the CTLA-4 Isoform Lacking Exons 2 and 3 Causes Autoimmunity

(2011) S. M. Liu et al.   JOURNAL OF IMMUNOLOGY

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

(2010) Kaan Harmankaya et al.   MEDICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD4+regulatory T cells require CTLA-4 for the maintenance of systemic tolerance

(2009) Randall H. Friedline et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-CTLA4 Antibody–Induced Lupus Nephritis

(2009) Fouad Fadel et al.   NEW ENGLAND JOURNAL OF MEDICINE